Search results for "Dox"

showing 10 items of 1345 documents

ChemInform Abstract: Radical Addition to Iminium Ions and Cationic Heterocycles

2015

Carbon-centered radicals represent highly useful reactive intermediates in organic synthesis. Their nucleophilic character is reflected by fast additions to electron deficient C=X double bonds as present in iminium ions or cationic heterocycles. This review covers diverse reactions of preformed or in situ-generated cationic substrates with various types of C-radicals, including alkyl, alkoxyalkyl, trifluoromethyl, aryl, acyl, carbamoyl, and alkoxycarbonyl species. Despite its high reactivity, the strong interaction of the radical’s SOMO with the LUMO of the cation frequently results in a high regioselectivity. Intra- and intermolecular processes such as the Minisci reaction, the Porta react…

Addition reactionNucleophileChemistryReactive intermediateCationic polymerizationPhotoredox catalysisIminiumRegioselectivityGeneral MedicineMedicinal chemistryMinisci reactionChemInform
researchProduct

Contribution of IL-17-producing {gamma}{delta} T cells to the efficacy of anticancer chemotherapy.

2011

IL-17 production by γδ T cells is required for tumor cell infiltration by IFN-γ–producing CD8+ T cells and inhibition of tumor growth in response to anthracyclines.

Adoptive cell transferMESH : AgedMESH : Equipment DesignCD8-Positive T-LymphocytesMESH: CatheterizationInterleukin-23MESH: Long-Term CareMice0302 clinical medicineMESH : CatheterizationT-Lymphocyte SubsetsMESH: NursingImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyInterferon gammaMESH: Quality of Health CareMESH: Professional Review OrganizationsMESH: AgedMESH : Gels0303 health sciencesMice Inbred BALB CCell DeathInterleukin-17MESH : Methylene BlueMESH : Quality of Health CareReceptors Antigen T-Cell gamma-deltaChemotherapy regimenMESH: Transplantation Autologous3. Good healthMESH: Cosmetic TechniquesTreatment Outcomemedicine.anatomical_structureMESH : Cadaver[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathSarcoma ExperimentalInterleukin 17MESH : DissectionMESH : Long-Term CareMESH: Nursing CareMESH: Adipose Tissuemedicine.drugSignal TransductionMESH : Transplantation Autologous[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Feasibility StudiesMESH: GelsT cellMESH : MaleImmunologyMESH: DissectionAntineoplastic AgentsBiologyMESH : NursingMESH : Adipose TissueArticleMESH : Facial Muscles03 medical and health sciencesInterferon-gammaLymphocytes Tumor-InfiltratingImmune systemAntigenCell Line TumorMESH: Patient Care PlanningmedicineMESH: CadaverAnimalsMESH : Patient Care Planning030304 developmental biologyMESH: Humansbusiness.industryMESH: Facial MusclesT-cell receptorMESH : HumansCorrectionMESH: MaleMice Inbred C57BLMESH : Cosmetic TechniquesDoxorubicinImmunologyCancer researchMESH : Nursing CareMESH : Professional Review OrganizationsbusinessMESH: Feasibility StudiesCD8030215 immunologyMESH: Methylene BlueMESH: Equipment Design
researchProduct

Fine chemistry by TiO2 heterogeneous photocatalysis

2021

Abstract Heterogeneous TiO2 photocatalysis is a promising technology based on the capability of the semiconducting material to generate charges upon irradiation of suitable energy. The photogenerated electrons and holes, in turn, induce redox reactions involving species adsorbed on the surface of the photocatalyst, giving rise to chemical transformations. The presence of highly oxidizing radicals, thus generated, has long led to consider TiO2 photocatalysis only a nonselective oxidation process. In fact, so far it is possible to find in the literature many examples of its use in the field of environmental remediation aimed at the degradation of harmful molecules, although the studies are al…

AdsorptionChemistryAlcohol oxidationOxidizing agentPhotocatalysisDegradation (geology)MoleculeAlkylationPhotochemistryRedox
researchProduct

Redox and autonomic responses to acute exercise-post recovery following Opuntia ficus-indica juice intake in physically active women

2021

Background: The aim of this study was to investigate if the supplementation with Opuntia ficus-indica (OFI) juice may affect plasma redox balance and heart rate variability (HRV) parameters following a maximal effort test, in young physically active women. Methods: A randomized, double blind, placebo controlled and crossover study comprising eight women (23.25 ± 2.95 years, 54.13 ± 9.05 kg, 157.75 ± 0.66 cm and BMI of 21.69 ± 0.66 kg/m2) was carried out. A juice containing OFI diluted in water and a Placebo solution were supplied (170 ml; OFI = 50 ml of OFI juice + 120 ml of water; Placebo = 170 ml beverage without Vitamin C and indicaxanthin). Participants consumed the OFI juice or Placebo…

Adult0301 basic medicineCactus pear juice supplementationOpuntia ficusTotal antioxidant capacityClinical nutritionmedicine.disease_causePlaceboYoung Adult03 medical and health scienceschemistry.chemical_compoundRedox balanceOxygen Consumption0302 clinical medicineAnimal scienceDouble-Blind MethodHigh frequencyHeart RatemedicineHumansHeart rate variabilityAutonomic nervous systemExerciseCross-Over StudiesNutrition and DieteticsSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportiveVitamin Cbusiness.industryOpuntiaHydrogen Peroxide030229 sport sciencesCrossover studyFruit and Vegetable JuicesHydroperoxideHydroperoxides030104 developmental biologychemistryOxidative stressOxidative streFemalebusinessLow frequencyOxidation-ReductionIndicaxanthinSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieOxidative stressResearch ArticleFood Science
researchProduct

Increased thioredoxin levels are related to insulin resistance in familial combined hyperlipidaemia

2015

BACKGROUND Thioredoxins (TRX) are major cellular protein disulphide reductases that are critical for redox regulation. Oxidative stress and inflammation play promoting roles in the genesis and progression of atherosclerosis, but until now scarce data are available considering the influence of TRX activity in familial combined hyperlipidaemia (FCH). Since FCH is associated with high risk of cardiovascular disease, the objective of the present study was to assess oxidative stress status in FCH patients, and evaluate the influence of insulin resistance (IR). MATERIALS AND METHODS A cohort of 35 control subjects and 35 non-related FCH patients were included, all of them nondiabetic, normotensiv…

AdultBlood GlucoseMale0301 basic medicinemedicine.medical_specialtyanimal structuresmedicine.medical_treatmentClinical BiochemistryHyperlipidemia Familial Combined030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compoundThioredoxins0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansTriglyceridesGlutathione Disulfidemedicine.diagnostic_testbusiness.industryInsulinCholesterol HDLCase-control studyCholesterol LDLGeneral MedicineGlutathioneMiddle Agedmedicine.diseaseGlutathioneOxidative Stress030104 developmental biologyEndocrinologychemistryCardiovascular DiseasesCase-Control StudiesGlutathione disulfideFemaleInsulin ResistanceThioredoxinLipid profilebusinessOxidative stressEuropean Journal of Clinical Investigation
researchProduct

Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma

1993

Twenty-two women affected by metastatic breast carcinoma have been treated with a combination of levo folinic acid 100 mg/m 2 plus 5-fluorouracil 450 mg/m 2 i.v. on day 1-2, and epidoxorubicin 75-90 mg/m 2 on day 2. This treatment cycle was repeated every 21-28 days. No patients had previously received chemotherapy for metastatic disease. Fourteen patients (64%) showed a major objective response with 3 complete (14%) and 11 partial responses (50%). Three patients showed a stabilization of disease and 5 (23%) progressed. All patients received ondansetron as antiemetic treatment which led to complete protection from vomiting in 68% of cases. Grade 1-2 diarrhea was recorded in 27% of the patie…

AdultCancer Research5-flurouracilDose-Response Relationship DrugLevo folinic acidCarcinomaLeucovorinBreast NeoplasmsMiddle AgedBreast cancerCarcinoma Intraductal NoninfiltratingOncologyEpidoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleFluorouracilAgedEpirubicin
researchProduct

Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group

2015

Purpose To determine, in the setting of advanced-stage of Hodgkin lymphoma (HL), whether relapses occur in the irradiated planning target volume and whether the definition of local radiation therapy (RT) used by the German Hodgkin Study Group (GHSG) is adequate, because there is no harmonization of field and volume definitions among the large cooperative groups in the treatment of advanced-stage HL. Methods and Materials All patients with residual disease of ≥2.5 cm after multiagent chemotherapy (CTX) were evaluated using additional positron emission tomography (PET), and those with a PET-positive result were irradiated with 30 Gy to the site of residual disease. We re-evaluated all sites o…

AdultCancer ResearchNeoplasm Residualmedicine.medical_treatmentPlanning target volumeIrradiated VolumeBleomycinFluorodeoxyglucose F18RecurrenceGermanyAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineCooperative groupRadiology Nuclear Medicine and imagingRadiation treatment planningCyclophosphamideEtoposideChemotherapyRadiationmedicine.diagnostic_testbusiness.industryRadiotherapy Planning Computer-AssistedRadiotherapy DosageMiddle AgedCombined Modality TherapyHodgkin DiseaseRadiation therapyOncologyDoxorubicinVincristinePositron emission tomographyPositron-Emission TomographyProcarbazinePrednisoneHodgkin lymphomaRadiopharmaceuticalsbusinessNuclear medicineInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

2008

Abstract Purpose: To determine the recommended dose, cardiac safety, and antitumor activity of nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and the anti-HER-2 monoclonal antibody trastuzumab in patients with HER-2-overexpressing locally advanced nonoperable breast cancer (LABC) and metastatic breast cancer (MBC). Experimental Design: Women with measurable, previously untreated, HER-2-overexpressing LABC and MBC with a baseline left ventricular ejection fraction (LVEF) >50% received weekly trastuzumab in combination with escalating doses of weekly paclitaxel and TLC-D99 every 3 weeks for 6 cycles. LVEF monitoring was done every 3 weeks for the first 18 weeks and every 8 w…

AdultCancer Researchmedicine.medical_specialtyHeart DiseasesPaclitaxelUrologyBreast NeoplasmsAntibodies Monoclonal HumanizedAsymptomaticDisease-Free Survivalchemistry.chemical_compoundBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinNeoplasm Metastasisskin and connective tissue diseasesAgedEjection fractionbusiness.industryAntibodies MonoclonalGenes erbB-2Middle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerUp-RegulationSurgeryOncologyPaclitaxelchemistryDoxorubicinHeart failureFemalemedicine.symptombusinessmedicine.drug
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct